A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-2
- Sponsors Janssen Research & Development
- 24 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Oct 2017 This study has been completed in Poland, according to European Clinical Trials Database record.
- 27 Sep 2017 This trial has been completed in Spain.